Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Servizo Galego De Saúde has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is assigned to 1 examiner and 1 art unit, keeping prosecution responsibility concentrated.
JAUHARI, SACHI is the busiest examiner, with 1 pending matter. Practitioners can direct docket monitoring and response preparation to that examiner and the requirements in the pending action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JAUHARI, SACHI | 1 | 60.0% | +80.0% |
| BEANE, RANDALL L | 1 | 32.9% | +36.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18290665 | CONNEXIN 43 FOR USE IN THE TREATMENT OF RETINOBLASTOMA PROTEIN POSITIVE TUMOURS | JAUHARI, SACHI | — |
| 18248101 | CONNEXIN 43 FOR USE IN THE TREATMENT OF A CANCER TYPE CHARACTERIZED BY THE ACTIVATION OF A MITOGEN-ACTIVATED PROTEIN KINASE | BEANE, RANDALL L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18290665 | CONNEXIN 43 FOR USE IN THE TREATMENT OF RETINOBLASTOMA PROTEIN POSITIVE TUMOURS | JAUHARI, SACHI | — |
| 18248101 | CONNEXIN 43 FOR USE IN THE TREATMENT OF A CANCER TYPE CHARACTERIZED BY THE ACTIVATION OF A MITOGEN-ACTIVATED PROTEIN KINASE | BEANE, RANDALL L | — |
| Art Unit | Apps |
|---|---|
| 1654 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18290665 | CONNEXIN 43 FOR USE IN THE TREATMENT OF RETINOBLASTOMA PROTEIN POSITIVE TUMOURS | JAUHARI, SACHI | 1654 | §103§112Other | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18248101 | CONNEXIN 43 FOR USE IN THE TREATMENT OF A CANCER TYPE CHARACTERIZED BY THE ACTIVATION OF A MITOGEN-ACTIVATED PROTEIN KINASE | BEANE, RANDALL L | 1654 | §102§103§112Other | Final Rejection | — | Pending | Apr 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialServizo Galego De Saúde has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Sachi Jauhari has the most, with 1 of Servizo Galego De Saúde's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
